Hartaj Singh

Oppenheimer & Co.

Image: Hartaj Singh

Hartaj Singh works at Oppenheimer. Before joining Oppenheimer, he was the director/biotechnology analyst for BTIG and a portfolio manager for Tecumseh Partners. As a senior project analyst at Visium Asset Management, he took advantage of fundamental discontinuities in Wall Street's perception of healthcare companies to return value to investors. Earlier, at Lehman Brothers, he was instrumental in the relaunch of the company's mid- and large-cap coverage. His tenure at Navigant Consulting enabled him to conduct hundreds of interviews with company executives and physicians, enhancing his understanding of their specific challenges. Early in his career, he was a strategic analyst for Johnson & Johnson, focusing on its global central nervous system/psychiatry franchise. While at ClinTrials Research, he coordinated clinical management for an anti-epileptic new drug application (NDA), and was the youngest clinical project manager to lead an NDA filing.

Recent Articles

Survey Results Positive for New HAE Drug 11/02/2023

Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report.

Recent Quotes

"We stay bullish on SNSS; there's potentially a multibillion market opportunity for SNS-062."

— Hartaj Singh, BTIG Research (5/10/16)
more >

"Near-term focus is on EU feedback on SNSS' vosaroxin application."

— Hartaj Singh, BTIG Research (4/18/16)
more >

"SNSS has enough cash runway until Q1/17."

— Hartaj Singh, BTIG Research (3/14/16)
more >

"SNSS presents a significant catalyst opportunity in 2016, as The Street is significantly undervaluing the potential for vosaroxin in the EU."

— Hartaj Singh, BTIG Research (2/19/16)
more >

"Yesterday, SNSS gave investors a positive update on its activities."

— Hartaj Singh, BTIG Research (11/6/15)
more >

"We continue to be intrigued by SNSS' pipeline of kinase inhibitors."

— Hartaj Singh, BTIG Research (10/8/15)
more >

"SNSS is significantly undervalued."

The Life Sciences Report Interview with Hartaj Singh (9/30/15)
more >

"We assume SNSS will file with the EU in Q4 EY/15."

— Hartaj Singh, BTIG Research (7/23/15)
more >

Due to permission requirements, not all quotes are shown.